ArticleTranslational lung cancer research2025
DNA damage and repair (DDR) gene mutation profiles in driver gene wild-type advanced non-small cell lung cancer and the predictive role of response to platinum-based chemotherapy.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: A pan-cancer perspective on precision oncology.Neoplasia (New York, N.Y.) · 2026Review
- Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer.Respiratory research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Platinum-based chemotherapy is an important therapeutic approach for patients with advanced non-small cell lung cancer (NSCLC) without driver gene mutations. DNA damage and repair (DDR) gene can mitigate platinum-induced DNA damage and induce resistance to platinum agents. The status of DDR gene in advanced driver gene wild-type NSCLC and their role in determining response and prognosis to platinum-based chemotherapy need to be investigated. This study used next-generation sequencing (NGS) to detect the mutation status of 47 DDR genes in seven DDR signaling pathways in driver gene wild-type NSCLC patients and to investigate their association with cisplatin-based chemotherapy. Methods: From November 2016 to September 2021, 182 cases of treatment-naïve patients with advanced driver gene wild-type NSCLC were prospectively studied. Either tumor tissue or serum circulating tumor DNA (ctDNA) was used to assess the status of 47 DDR gene using NGS. The primary endpoint was objective response rate (ORR), and the secondary endpoints were progression-free survival (PFS) and overall survival (OS). The DDR mutation was analyzed in relation to response to platinum-based chemotherapy and clinical outcomes. Results: There were 136 of 182 patients who received first-line platinum-based chemotherapy included. DDR mutations from 101 NSCLC patients were sequenced and analyzed. The median follow-up time was 17.6 (interquartile range, 15.4-19.8) months. There were 66.33% of patients in this cohort having a DDR gene mutation. When treated with first-line platinum-based chemotherapy, the ORR of DDR-mutant (DDRmut) patients was significantly higher than that of DDR-wild type (DDRwt) patients (52.2% Conclusions: There was a high prevalence of DDR mutation in advanced NSCLC harboring wild-type epidermal growth factor receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.